CD16xCD33 BiKE

CD16xCD33 BiKE is a fully humanized bispecific antibody construct known as a "bispecific killer cell engager." It binds simultaneously to **CD16** (FcγRIIIa) on natural killer (NK) cells and **CD33** on target cells, primarily malignant myeloid cells. This dual-targeting enables the activation and redirection of NK cells to kill CD33-positive cells by engaging NK cell-mediated cytotoxicity, including degranulation and cytokine production (such as TNF-α and IFN-γ). The drug is being studied as a targeted immunotherapy for **acute myeloid leukemia (AML)**, **biphenotypic acute lymphoblastic leukemia (ALL)** that expresses CD33, and **myelodysplastic syndrome (MDS)**. Preclinical studies and early-phase trials have shown that CD16xCD33 BiKE enhances NK cell effector functions and promotes lysis of CD33^+^ leukemic cells and myeloid-derived suppressor cells. Potential uses include maintenance therapy or as a bridge to hematopoietic stem cell transplantation in pediatric and adult patients[1][2][3].

Other names

bispecific killer cell engager CD16xCD33